Fundamental Analysis of TIMBER PHARMACEUTICALS INC(NYSEARCA:TMBR) stock

Fundamental Rating

Overall TMBR gets a fundamental rating of 2 out of 10. We evaluated TMBR against 198 industry peers in the Pharmaceuticals industry. The financial health of TMBR is average, but there are quite some concerns on its profitability. TMBR has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

TMBR had negative earnings in the past year.

In the past year TMBR has reported a negative cash flow from operations.

In the past 5 years TMBR always reported negative net income.

TMBR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of TMBR (-116.71%) is worse than 84.31% of its industry peers.

With a Return On Equity value of -195.55%, TMBR is not doing good in the industry: 73.04% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-116.71%
ROE	-195.55%
ROIC	N/A

ROA(3y)-234.54%

ROA(5y)-276.44%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TMBR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TMBR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, TMBR has more shares outstanding

The number of shares outstanding for TMBR has been increased compared to 5 years ago.

There is no outstanding debt for TMBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

TMBR has an Altman-Z score of -7.84. This is a bad value and indicates that TMBR is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -7.84, TMBR is doing worse than 74.02% of the companies in the same industry.

TMBR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.84

ROIC/WACCN/A

WACC9.15%

2.3 Liquidity

TMBR has a Current Ratio of 2.45. This indicates that TMBR is financially healthy and has no problem in meeting its short term obligations.

TMBR has a worse Current ratio (2.45) than 63.24% of its industry peers.

A Quick Ratio of 2.45 indicates that TMBR has no problem at all paying its short term obligations.

TMBR has a Quick ratio (2.45) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.45
Quick Ratio	2.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TMBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.02%, which is quite impressive.

Looking at the last year, TMBR shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

TMBR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.36% yearly.

EPS 1Y (TTM)58.02%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-0.09%

Revenue 1Y (TTM)-100%

Revenue growth 3Y10.06%

Revenue growth 5Y-4.36%

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to decrease by -438.52% on average over the next years. This is quite bad

TMBR is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -41.42% yearly.

EPS Next Y-2636.84%

EPS Next 2Y-438.52%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TMBR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TMBR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

TMBR's earnings are expected to decrease with -438.52% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-438.52%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TMBR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TIMBER PHARMACEUTICALS INC

NYSEARCA:TMBR (11/28/2023, 7:04:00 PM)

Premarket: 0.3532 +0.01 (+3.09%)

0.3426

+0 (+0.74%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.04M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-116.71%
ROE	-195.55%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.45
Quick Ratio	2.45
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)58.02%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-2636.84%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3Y10.06%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

TIMBER PHARMACEUTICALS INC (TMBR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens